Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

The stock's fall snapped a two-day winning streak.

Currently trading with a volume of 891,270, the VRTX's price is down by -3.75%, now at $451.64. RSI readings suggest the stock is currently is currently neutral between overbought and oversold.

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

There are always new frontiers in health care: diseases whose treatment and cures still elude us; biological and medical ...

Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious opportunities, particularly with ...

SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...

The raffle ends on January 31, 2025. 10th Annual Glow Ride for CF: A Record-Breaking Success The 10th Annual Glow Ride for CF, presented by Vertex Pharmaceuticals, was held on September 21, 2024, in ...

Under the terms of the agreement announced Wednesday, the Gates Foundation will invest up to $50 million to support the program's advancement into clinical testing. Tessera has said one of its goals ...

Chronic pain can have huge impacts on patients and their families. We discuss its prevalence and emerging therapies with Asal ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Broad Arrow Delivers 75% Year-Over-Year Growth in 2024 with $316 Million in Transactions Across Auctions, Private Sales, and ...